Suppr超能文献

经支气管镜获取肿瘤样本的基因表达情况可预测晚期不可手术肺癌的预后。

Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer.

机构信息

Radiotherapy Clinic and Teaching Hospital, M. Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland.

出版信息

PLoS One. 2012;7(7):e41379. doi: 10.1371/journal.pone.0041379. Epub 2012 Jul 27.

Abstract

BACKGROUND

Several studies have shown the prognostic and predictive potential of molecular markers in combined therapy for lung cancer. Most of them referred, however, to operable early stage NSCLC. The aim of the present study is to correlate the expression of multiple mRNA markers in bronchoscopy obtained cancer specimens with clinical outcome of advanced lung cancer.

METHODS

Bronchoscopy cancer specimens were taken from 123 patients with radiological diagnosis of advanced lung tumor. Out of 123 patients 50 were diagnosed with squamous cell cancer, 17 with adenocarcinoma, 12 with NOS, 32 with SCLC and one with large cell neuroendocrinal cancer. In 11 patients other tumours were diagnosed. The group was heterogeneous with respect to clinical stage, performance of the patients and treatment. Quantitative real time PCR was carried out by ABI 7900 HT machine, with Universal Probe Library (Roche) fluorescent probes. The genes selected for the analysis were ERCC1, EGFR, BRCA1, CSF1, CA9, DUSP6, STAT1, ERBB3, MMD, FN1, and CDKN1B.

RESULTS

More than 50 ng of RNA (the amount considered sufficient for the analysis) was isolated in 82 out of 112 lung cancer specimens (73%), including 60/80 (75.0%) of NSCLC specimens and 22/32 (68,7%) of SCLC samples. The highest Cohen's κ coefficient for discrimination between small cell, squamous cell and adenocarcinoma was found for CDKN1B, CSF and EGFR1 (κ = 0.177, p = 0.0041). A multivariate Cox regression model has shown a significant impact of clinical stage (p<0.001, RR = 4.19), ERCC1 (p = 0.01, RR = 0.43) and CA9 (p = 0.03, RR = 2.11) expression on overall survival in a group of 60 patients with NSCLC.

CONCLUSION

These results show the feasibility of multiple gene expression analysis in bronchoscopy obtained cancer specimens as prognostic markers in radiotherapy and chemotherapy for advanced lung cancer. A limiting factor was relatively high proportion of samples from which sufficient amount of RNA could not be isolated.

摘要

背景

多项研究表明,分子标志物在肺癌联合治疗中的预后和预测潜力。然而,大多数研究都涉及可手术的早期非小细胞肺癌。本研究的目的是将支气管镜活检癌症标本中多个 mRNA 标志物的表达与晚期肺癌的临床结果相关联。

方法

对 123 例影像学诊断为晚期肺部肿瘤的患者进行支气管镜癌症标本采集。在 123 例患者中,50 例被诊断为鳞状细胞癌,17 例为腺癌,12 例为NOS,32 例为小细胞肺癌,1 例为大细胞神经内分泌癌。在 11 例患者中诊断为其他肿瘤。该组在临床分期、患者表现和治疗方面存在异质性。采用 ABI 7900 HT 机器和通用探针库(罗氏)荧光探针进行实时定量 PCR。选择用于分析的基因包括 ERCC1、EGFR、BRCA1、CSF1、CA9、DUSP6、STAT1、ERBB3、MMD、FN1 和 CDKN1B。

结果

在 112 例肺癌标本中有 82 例(73%)分离出超过 50ng 的 RNA(分析所需的量),包括 60/80(75.0%)例非小细胞肺癌标本和 22/32(68.7%)例小细胞肺癌样本。用于区分小细胞癌、鳞状细胞癌和腺癌的最大 Cohen's κ 系数为 CDKN1B、CSF 和 EGFR1(κ=0.177,p=0.0041)。多变量 Cox 回归模型显示,在 60 例非小细胞肺癌患者中,临床分期(p<0.001,RR=4.19)、ERCC1(p=0.01,RR=0.43)和 CA9(p=0.03,RR=2.11)表达对总生存期有显著影响。

结论

这些结果表明,在支气管镜活检癌症标本中进行多个基因表达分析作为放疗和化疗治疗晚期肺癌的预后标志物是可行的。一个限制因素是相对较高比例的样本无法分离出足够数量的 RNA。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec0/3407200/c20d9f66d3d1/pone.0041379.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验